Sentinel lymph node biopsy with blue patent more imprinted in the axillary stage of breast cancer in a hospital of high complexity
DOI:
https://doi.org/10.35434/rcmhnaaa.2021.142.1064Keywords:
Sentinel lymph node, Imprint, Breast cancer, Neoplasms, Biopsy, Oncology Service, HospitalAbstract
Objetive: To analyze the main clinical-pathological characteristics of patients with breast carcinoma in whom a sentinel lymph node biopsy was performed with patent blue plus imprint in the axillary staging. The study. This descriptive series evaluated a series of 20 cases of patients with an anatomopathological diagnosis of infiltrating ductal carcinoma treated in the area of Oncological Surgery of the Hospital of High Complexity "Virgen de la Puerta" EsSalud, La Libertad - Peru, during the period February 2017 until January 2018. Findings: The sensitivity and specificity of the sentinel lymph node imprint was 75% respectively. The positive and negative predictive value was 67% and 82% respectively. The positive and negative likelihood ratio was 3.0 and 0.33. The Kappa index was 0.2 of considered as a concordance index. Conclusions. The sentinel lymph node technique is a good alternative for the management of breast cancer, since it avoids unnecessary surgical interventions.